Cargando…

P1436: AGEING IMPACTS HYDROXYCARBAMIDE DOSING IN PATIENTS WITH SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales:	Doss, Isabelle, Ekong A, Anietie, Stuart-Smith, Sara, Dekreuk, Arne, Azoujibenjamin, Sheila, Seviar, Dale, Gardner, Kate, Kesse-Adu, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430612/ http://dx.doi.org/10.1097/01.HS9.0000972628.14148.90

Ejemplares similares

P1422: PREVALENCE AND RISK FACTORS FOR RETINOPATHY IN SICKLE CELL DISEASE
por: Gardner, Kate, et al.
Publicado: (2023)

P1419: A SINGLE CENTRE PERSPECTIVE ON PREGNANCY OUTCOMES AND SICKLE CELL COMPLICATIONS IN WOMEN ON HYDROXYCARBAMIDE PERI-CONCEPTION.
por: Gregori, Maria, et al.
Publicado: (2023)

5612984 AUDIT OF TRUST COMPLIANCE WITH BSH GUIDELINES FOR UTILISATION OF HYDROXYCARBAMIDE IN PATIENTS WITH SICKLE CELL DISEASE
por: Barker, R., et al.
Publicado: (2023)

Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease
por: Wiles, NM, et al.
Publicado: (2009)

P123: A SYSTEMATIC REVIEW OF THE BARRIERS TO UPTAKE AND ADHERENCE TO HYDROXYCARBAMIDE FROM THE PERSPECTIVE OF CHILDREN AND ADULTS WITH SICKLE CELL DISEASE, PARENTS AND CLINICIANS.
por: Clark, C
Publicado: (2022)

Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility
por: Joseph, Laure, et al.
Publicado: (2023)

A meta‐analysis of toxicities related to hydroxycarbamide dosing strategies
por: Mathias, Joacy G., et al.
Publicado: (2020)

P1436: DEVELOPMENT OF A BETA-GLOBIN GENE REPLACEMENT STRATEGY AS A THERAPEUTIC APPROACH FOR ΒETA-THALASSEMIA
por: Wienert, B., et al.
Publicado: (2022)

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008)

VWF–ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion
por: Fogarty, Helen, et al.
Publicado: (2023)

Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings
por: Inusa, Baba Psalm Duniya, et al.
Publicado: (2018)

Hydroxycarbamide‐related cutaneous ulcer complicated by osteomyelitis
por: England, James T., et al.
Publicado: (2021)

1436. Use of Whole Genome Sequencing to Characterize Antimicrobial-resistant Salmonella Berta Isolates from Clinical and Retail Meat Sources
por: M’ikanatha, Nkuchia M, et al.
Publicado: (2020)

Hydroxycarbamide: Worsening thrombocytopenia and unmasking of lymphopenia: case report
Publicado: (2021)

Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms
por: Contreras Castillo, Stephania, et al.
Publicado: (2021)

5613294 BASELINE PATIENT CHARACTERISTICS FROM A UK EARLY ACCESS TO MEDICINES SCHEME (EAMS) WITH VOXELOTOR, A HBS POLYMERIZATION INHIBITOR, FOR THE TREATMENT OF HEMOLYTIC ANEMIA DUE TO SICKLE CELL DISEASE
por: Eleftheriou, P., et al.
Publicado: (2023)

Complete genome sequence of the sand-sediment actinobacterium Nocardioides dokdonensis FR1436(T)
por: Kwak, Min-Jung, et al.
Publicado: (2017)

Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

Sustained Regression of Hydroxycarbamide Induced Actinic Keratoses after Switching to Anagrelide
por: Gaitanis, Georgios, et al.
Publicado: (2018)

Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
por: Błocka-Gumowska, Monika, et al.
Publicado: (2019)

Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
por: Mathur, Abhinav, et al.
Publicado: (2022)

1436. Interventions to Address the Global Underreporting of Pediatric and Adolescent Tuberculosis: A Systematic Review
por: Linn, Alexandra R, et al.
Publicado: (2022)

Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings
por: Strunk, Crawford, et al.
Publicado: (2020)

Hydroxycarbamide overdose: Marrow suppression presenting as neutropenia following accidental overdose: case report
Publicado: (2020)

Gilteritinib/hydroxycarbamide/remdesivir: Neutropenia, lack of efficacy and off-label use: case report
Publicado: (2021)

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
por: Brusson, Mégane, et al.
Publicado: (2018)

Study on risk factors (predisposing factors) for poor diabetes control during Hajj (1436/2015) in people with diabetes
por: Hasan, Gulshad, et al.
Publicado: (2016)

The protein tyrosine phosphatase 1B inhibitor MSI-1436 stimulates regeneration of heart and multiple other tissues
por: Smith, Ashley M., et al.
Publicado: (2017)

Comparative Transcriptomic Analysis of Streptococcus thermophilus TH1436 and TH1477 Showing Different Capability in the Use of Galactose
por: Giaretta, Sabrina, et al.
Publicado: (2018)

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023)

Whole-Genome Sequences of Streptococcus thermophilus Strains TH1435 and TH1436, Isolated from Raw Goat Milk
por: Treu, Laura, et al.
Publicado: (2014)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

1436. Effect of Personal Protective Equipment Conservation Due to COVID-19 on Multidrug Resistant Organisms in a Hospital Group
por: Fox, Josephine, et al.
Publicado: (2023)

Chloroquine/dalteparin sodium/hydroxycarbamide: Prolongation of the QTc interval secondary to off-label use and lack of efficacy: case report
Publicado: (2021)

A Microbiota-Dependent Response to Anticancer Treatment in an In Vitro Human Microbiota Model: A Pilot Study With Hydroxycarbamide and Daunorubicin
por: Hobson, Claire Amaris, et al.
Publicado: (2022)

P-059: TRIAL IN PROGRESS: THE RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 RESOLVE TRIAL INVESTIGATING THE EFFICACY OF VOXELOTOR WITH STANDARD OF CARE IN THE RESOLUTION OF LEG ULCERS IN PATIENTS WITH SICKLE CELL DISEASE
por: C., MINNITI, et al.
Publicado: (2022)

P1497: BURDEN OF SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Jastaniah, W., et al.
Publicado: (2022)

P1435: OUTCOMES OF COVID-19 INFECTION IN INDIVIDUALS WITH SICKLE CELL DISEASE OR SICKLE CELL TRAIT: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Ferreira Michelon, Isabella, et al.
Publicado: (2023)

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
por: Godfrey, Anna L., et al.
Publicado: (2018)

MSI-1436 improves EMS adipose derived progenitor stem cells in the course of adipogenic differentiation through modulation of ER stress, apoptosis, and oxidative stress
por: Bourebaba, Lynda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n09leref32frv51ebb7pbft638